Gosselies, Belgium, July 15, 2024 – EXO-Harvest, an affiliate of convEyXO, is thrilled to announce the successful launch of its cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production, in partnership with IPRATECH. The platform is now fully operational, marking a significant milestone in joint efforts to advance biotechnological solutions through engineering excellence. [Read more…]
BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell
Tokyo, Japan and Mont-Saint-Guibert, Belgium – BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. [Read more…]
Takeda and Alloy Therapeutics to Co-Develop iPSC-Derived CAR-T and CAR-NK Products (iCAR-T and iCAR-NK)
TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]
Exclusive Investment Opportunity in Mexico with PRMedica Global
PRMedica Global, a distinguished British-incorporated company based in Los Cabos, Mexico, invites you to explore a premium investment opportunity in the growing field of regenerative medicine. With a specialized focus on advanced treatments using stem cells, exosomes, peptides, natural killer (NK) cells, and CAR-T cell therapies, PRMedica is at the forefront of medical innovation. Its treatments are designed to target a wide spectrum of health concerns, including orthopedic and musculoskeletal disorders, arthritis, autoimmune diseases, anti-aging solutions, neurological conditions, and more. [Read more…]
Cynata Introduces Critical Innovation into MSC Manufacturing
In the context of cell therapy, product innovation is the introduction of a cellular product that is new or has significantly improved characteristics or intended uses. Over the past decade, a great deal of attention has been given to cell therapy product innovation, as demonstrated by the thousands of cell therapy products that have now entered clinical trials worldwide.
In contrast, process innovation refers to the implementation of a new or significantly improved production or delivery method. In the context of cell therapy, process innovation has received much less attention from the marketplace. [Read more…]
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 339
- Next Page »